This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Clovis Completes Enrollment in Late-Stage Ovarian Cancer Study
by Zacks Equity Research
Clovis (CLVS) is developing Rubraca as monotherapy as well as in combination with Bristol-Myers' Opdivo as first-line maintenance treatment for ovarian cancer in the phase III ATHENA study.
Why Is Clovis (CLVS) Down 17.2% Since Last Earnings Report?
by Zacks Equity Research
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AstraZeneca/Merck's Lynparza Get FDA Nod for Prostate Cancer
by Zacks Equity Research
FDA approves AstraZeneca (AZN)/Merck's (MRK) PARP inhibitor Lynparza for HRR gene-mutated metastatic castration-resistant prostate cancer. The approval was based on data from the phase III PROfound study.
Clovis' (CLVS) Rubraca Gets FDA Approval for Prostate Cancer
by Zacks Equity Research
Clovis' (CLVS) PARP inhibitor, Rubraca, receives approval from the FDA as monotherapy to treat BRCA-mutant metastatic castration-resistant prostate cancer.
Is Clovis Oncology (CLVS) Stock a Solid Choice Right Now?
by Zacks Equity Research
Clovis Oncology (CLVS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Clovis (CLVS) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Clovis (CLVS) reports first-quarter 2020 results. The company's sole marketed drug, Rubraca, drives revenues. Shares up.
Clovis Oncology (CLVS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Clovis (CLVS) delivered earnings and revenue surprises of 0.78% and 1.84%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in Clovis Oncology (CLVS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
Clovis (CLVS) Upgraded to Buy: Here's Why
by Zacks Equity Research
Clovis (CLVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Clovis Oncology (CLVS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Clovis Oncology (CLVS) closed the most recent trading day at $6.10, moving +0.49% from the previous trading session.
Why Is Clovis (CLVS) Down 41.6% Since Last Earnings Report?
by Zacks Equity Research
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is the Options Market Predicting a Spike in Clovis Oncology (CLVS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
Clovis Oncology (CLVS) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Clovis Oncology (CLVS) closed the most recent trading day at $4.50, moving +0.45% from the previous trading session.
Clovis Oncology (CLVS) Stock Moves -1.59%: What You Should Know
by Zacks Equity Research
Clovis Oncology (CLVS) closed the most recent trading day at $6.17, moving -1.59% from the previous trading session.
Trevena's NDA for Pain Drug Oliceridine Gets FDA Acceptance
by Zacks Equity Research
FDA accepts Trevena's (TRVN) NDA for opioid analgesic, oliceridine, re-submitted last month. A decision is expected in August.
How to Find Strong Cheap Stocks to Buy Under $10 Despite Coronavirus Fears
by Benjamin Rains
The market selloff might continue amid coronavirus uncertainty. But that doesn't mean investors should stop buying, or adding stocks to their watchlists. Here's how to find strong cheap stocks under $10 to buy...
Perrigo (PRGO) Misses Q4 Earnings Estimates, Tops Revenues
by Zacks Equity Research
Perrigo (PRGO) reports mixed fourth-quarter 2019 results. The addition of products following Ranir acquisition boosts sales in the quarter. Stock declines.
Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Miss Estimates
by Zacks Equity Research
Sarepta (SRPT) reports wider year-over-year loss. However, revenues increase year over year.
Arena Pharmaceuticals (ARNA) Q4 Earnings Miss, Revenues Top
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) incurs wider-than-expected loss in the fourth quarter of 2019 while revenues beat estimates.
Clovis (CLVS) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Clovis (CLVS) reports mixed fourth-quarter 2019 results. The company's sole marketed drug, Rubraca, drives revenues. Shares down.
Clovis Oncology (CLVS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Clovis (CLVS) delivered earnings and revenue surprises of -12.42% and 1.35%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Exelixis (EXEL) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are looking forward to Cabometyx's performance and pipeline updates, when Exelixis (EXEL) reports Q4 results.
Intellia (NTLA) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Intellia (NTLA) is likely to provide an update on the IND application for its lead candidate NTLA-2001, currently being developed to address transthyretin amyloidosis.
Guardant Health (GH) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
During Guardant Health's (GH) Q4 earnings call, investors' focus will be on the updates related to Guardant360 test and the colorectal cancer screening rates of its LUNAR-2 blood test.